On March 28, 2024, Bristol-Myers Squibb Company has filed a definitive proxy statement soliciting proxies and urged the shareholders to vote against the shareholder proposal from John Chevedden, asking the Board of Directors to adopt a policy requiring the 5 named executive officers (NEOs) to retain a significant percentage of stock acquired through equity pay programs until reaching normal retirement age and to report to shareholders regarding the policy in the Company?s next annual meeting proxy at its annual general meeting of shareholders scheduled to be held on May 7, 2024.